Conference Day One - Wednesday, 4 December

TO VIEW FULL SESSION DETAILS PLEASE DOWNLOAD THE FULL EVENT GUIDE HERE

7.20 Check-In & Coffee

8.20 Chair’s Opening Remarks

  • Luca Biasco Vice President, Translational Sciences, Nvelop Therapeutics

Plenary Session: Clinical Highlights from 2024

8.20 Making the Leap to Phase 3 Studies: Overcoming Clinical Development & Operational Challenges

  • Jeffrey Cehelsky Vice President, Development Operations, Intellia Therapeutics

8.50 From Innovation to Commercialization – CRISPR Medicine Manufacturing Solutions for the Next Decade

  • Max Sellman Senior Product Manager, Gene Editing, Aldevron

9.20 Leveraging EBT-101 Preclinical & Early Clinical Development for New In Vivo Multiplex Editing Programs

  • Ryo Takeuchi Senior Director, Genome Editing, Excision BioTherapeutics Inc.

9.50 Panel Discussion: Ensuring Diversity, Equity & Inclusivity in Gene Editing Clinical Trials

10.30 Morning Refreshments & Speed Networking

Innovation & Early Development Track

Translating to the Clinic Track

Enabling Precise Small- and Large- Cargo In Vivo Delivery

Moderator: Joseph Nabhan, Vesigen Therapeutics

Advancing Assay Development and Safety
Monitoring Methods

Moderator: Jeffrey Cehelsky, Intellia Therapeutics

11.30 Novel Delivery Platforms for Efficient and Specific In Vivo Delivery of Genome Editing Payloads

Luca Biasco, Vice President, Translational Sciences, Nvelop Therapeutics

11.30 Leveraging Duplex Sequencing for Highly Sensitive
Off-Target Assessment

Barrett Nuttall, Director, AstraZeneca

12.00 Highly Efficient Integrase Technology for Site-Specific
Genomic Integration of Large DNA Payload

Omid Harandi, Chief Scientific Officer, Komo Biosciences

12.30 Clinical Safety Monitoring Strategies for Gene Editing
Therapies

Priya Chockalingam, Vice President, Head of Clinical
Bioanalytics & Translational Sciences, Beam Therapeutics

12:30 Lunch Briefing Hosted by Edilytics

Synopsis

Invite-only networking lunch hosted by Edilytics. Presentation details to be announced shortly.

If you are interested in attending, please contact Charlotte Hodgson at sponsor@hansonwade.com

12:30 Lunch & Networking

Innovation & Early Development Track

Translating to the Clinic Track

Optimizing Guide Molecules & Advancing Analytical Platforms

Moderator: Joseph Nabhan, Vesigen Therapeutics

Overcoming Key Regulatory & Translation Challenges

Moderator: Jeffrey Cehelsky, Intellia Therapeutics

1.30 The CRISPR Analytics Platform™: A New Biosensor
Tool Providing Advanced In Vitro CRISPR Analytics To
Maximize Gene Editing and Bioprocessing Outcomes

Jason Lehmann, Senior Product Marketing Manager, CRISPR
QC

1.30 Discovery and HG-PRECISE Engineering of hfCas12Max High-Fidelity Nuclease and Pre-clinical Testing in Mouse and NHP Models to Support M.U.S.C.L.E. Trial for DMD

TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics

2.00 Prime Editing pegRNA: Optimizing Guides

Andrew Anzalone, Director, Head of Prime Editing Platform,
Prime Medicine

2.00 Innovation in Guide RNA Manufacturing: Dual
Purification Technique

Amanda Haas, Business Development Manager, Nucleic Acid
Solutions, Agilent Technologies

2.30 Optimizing Guide RNAs for In Vivo Editing

Bryant Chica, Scientist II, Analytical Chemistry & Structural
Biology, Editas Medicine

2.10 Extended Audience Discussion: Outlining a Path from
Preclinical Models to the Clinic

Vivian Choi, Head of Liver, Metabolic, Lung, Eye & Ear
Disease Unit, Prime Medicine

3.00 Afternoon Refreshments

Plenary Session: Intellectual Property Protection, Patent Disputes & Technology Licensing

3.40 Charting a ‘Freedom to Operate’ as a Start-Up Gene Editing Biotech

4.10 Panel Discussion: Licensing Deals for Gene Editing Therapeutic & Delivery Technologies

4.50 Chair’s Closing Remarks

5.00 End of Day One

5.00 Drinks Reception & Scientific Poster Session

WORKSHOP DAY
REGISTER
CONFERENCE DAY 2